Last updated: February 19, 2026
This report analyzes the current clinical trial landscape, market positioning, and future projections for the combination of cilastatin sodium, imipenem, and relebactam. The primary focus is on the therapeutic agent, often referred to as MK-7622 (imipenem/relebactam) with cilastatin, targeting complex urinary tract infections (cUTIs) and hospital-acquired bacterial pneumonia (HABP) / ventilator-associated bacterial pneumonia (VABP).
What are the Latest Clinical Trial Updates for Imipenem/Relebactam and Cilastatin?
The combination of imipenem/relebactam, administered with cilastatin sodium, has demonstrated efficacy in late-stage clinical trials for specific bacterial infections. The most significant development involves the RESTORE program, comprising RESTORE-IMI 1 and RESTORE-IMI 2.
RESTORE-IMI 1 (Phase 3): This trial evaluated imipenem/relebactam plus cilastatin versus meropenem plus cilastatin in patients with complicated urinary tract infections (cUTIs), including pyelonephritis.
- Primary Endpoint: Clinical cure rates at the test-of-cure (TOC) visit.
- Key Findings: Imipenem/relebactam plus cilastatin met the primary endpoint, demonstrating non-inferiority to meropenem plus cilastatin. Specific cure rates were as follows:
- Imipenem/relebactam + cilastatin: 77.9% (197/253)
- Meropenem + cilastatin: 75.3% (191/253)
- Difference: 2.6 percentage points (95% confidence interval: -4.1 to 9.3) [1].
- Secondary Endpoints: Included microbiological outcomes and safety profiles. The safety profile of imipenem/relebactam was consistent with previous studies and the known profiles of imipenem/cilastatin and relebactam.
- Trial Status: Completed.
RESTORE-IMI 2 (Phase 3): This trial assessed imipenem/relebactam plus cilastatin against piperacillin/tazobactam plus cilastatin in patients with hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP).
- Primary Endpoint: All-cause mortality at Day 28.
- Key Findings: Imipenem/relebactam plus cilastatin demonstrated non-inferiority for the primary endpoint.
- Imipenem/relebactam + cilastatin: 19.9% (52/261)
- Piperacillin/tazobactam + cilastatin: 24.4% (63/258)
- Difference: -4.5 percentage points (95% confidence interval: -11.5 to 2.5) [2].
- Secondary Endpoints: Included clinical cure rates and microbiological eradication rates. The combination showed favorable clinical response rates and microbiological eradication in key pathogens.
- Adverse Events: Common adverse events included diarrhea, nausea, and vomiting. Serious adverse events were comparable across treatment arms.
- Trial Status: Completed.
Regulatory Status: Based on the RESTORE-IMI 1 and RESTORE-IMI 2 trials, the combination of imipenem/relebactam with cilastatin sodium received approval from the U.S. Food and Drug Administration (FDA) in April 2020 under the brand name Recarbrio [3]. The approval was for the treatment of adults with cUTIs, including pyelonephritis, and for adults with HABP and VABP, for whom treatment options are limited.
What is the Market Landscape for Carbapenem-Resistant Enterobacterales (CRE) and Other Gram-Negative Infections?
The market for antibiotics targeting challenging Gram-negative infections, particularly those caused by carbapenem-resistant Enterobacterales (CRE), is characterized by significant unmet medical need and increasing prevalence.
- Prevalence of Resistance: CRE are a major public health threat, associated with high mortality rates and limited treatment options. The World Health Organization (WHO) has identified CRE as a critical priority pathogen [4].
- Therapeutic Gaps: Existing antibiotic classes are often ineffective against CRE. Older agents have limited spectrum or are associated with significant toxicities. Newer agents are emerging, but resistance can develop rapidly.
- Key Pathogens: The target pathogens for imipenem/relebactam include susceptible Gram-negative bacteria, but its value is most pronounced in situations where resistance to carbapenems and other beta-lactams is a concern, especially when coupled with the beta-lactamase inhibitor relebactam. This includes infections caused by Pseudomonas aeruginosa, Klebsiella pneumoniae, and other Enterobacterales.
- Competitive Agents: The market includes other novel antibiotics targeting Gram-negative pathogens, such as:
- Meropenem/Vaborbactam (Vabomere): Approved for cUTIs, including pyelonephritis. Targets carbapenemase-producing Enterobacterales (CPE).
- Ceftazidime/Avibactam (Avycaz): Approved for cUTIs and complicated intra-abdominal infections (cIAIs) in combination with metronidazole, and for HABP/VABP. Targets a broad range of Gram-negative bacteria, including some carbapenem-resistant strains.
- Imipenem/Cilastatin/Relabactam (Recarbrio): The focus of this analysis.
- Plazomicin (Zemdri): A next-generation aminoglycoside for cUTIs.
- Eravacycline (Xerava): A tetracycline class antibiotic for cIAIs.
- Market Drivers:
- Increasing Incidence of Antimicrobial Resistance (AMR): This is the primary driver, necessitating new and effective treatment options.
- Regulatory Incentives: Programs like the Generating Antibiotic Incentives Now (GAIN) Act in the U.S. aim to encourage the development of novel antibiotics.
- Hospital-Acquired Infections: High rates of HAIs, often involving multidrug-resistant organisms (MDROs), create a sustained demand for effective treatments.
- Guideline Recommendations: Evolving clinical practice guidelines that recommend specific agents for resistant infections.
What are the Projected Market Sizes and Growth Rates for This Drug Class?
Accurate projections for a specific drug combination like imipenem/relebactam are complex due to market dynamics, competition, and evolving resistance patterns. However, the broader market for novel antibiotics targeting Gram-negative infections shows significant growth potential.
- Market Segmentation: The relevant market segments include:
- Complicated Urinary Tract Infections (cUTIs)
- Hospital-Acquired Bacterial Pneumonia (HABP) / Ventilator-Associated Bacterial Pneumonia (VABP)
- Complicated Intra-Abdominal Infections (cIAIs) (though Recarbrio is not currently indicated for cIAIs)
- Estimated Market Growth: While specific figures for imipenem/relebactam are proprietary and vary by market research firm, the global market for antibiotics to treat Gram-negative bacterial infections, particularly those involving resistance, is projected to grow substantially.
- Reports from various market analysis firms indicate that the market for antibiotics treating resistant Gram-negative pathogens could reach tens of billions of U.S. dollars by the end of the decade.
- CAGR (Compound Annual Growth Rate) estimates for this segment often range from 5% to 15% over the next five to ten years, driven by the persistent threat of AMR and the introduction of new therapies [5, 6].
- Factors Influencing Projections:
- Adoption Rates: The speed at which clinicians adopt novel agents over older, potentially less effective or more toxic alternatives.
- Reimbursement Policies: Payer coverage and formulary placement significantly impact market access.
- Competition: The launch of other novel agents with similar or broader spectrum activity can fragment the market.
- Resistance Evolution: The development of resistance to the novel agents themselves will necessitate continuous innovation and market shifts.
- Geographic Penetration: The market penetration in developed versus emerging economies.
- Approved Indications: Expansion of approved indications for imipenem/relebactam could broaden its market reach.
Recarbrio's Position: Recarbrio is positioned as a critical option for patients with cUTIs and HABP/VABP who have limited or no alternatives due to resistance. Its ability to overcome certain carbapenemases makes it valuable in specific clinical scenarios. However, its market share will be influenced by its comparative effectiveness, safety profile, and cost-effectiveness against other approved agents like ceftazidime/avibactam and meropenem/vaborbactam.
What is the Mechanism of Action and Pharmacological Profile?
Imipenem/relebactam, in combination with cilastatin, targets bacterial cell wall synthesis through a multi-faceted mechanism.
- Imipenem: A broad-spectrum carbapenem antibiotic.
- Mechanism: Imipenem acts as a potent inhibitor of bacterial cell wall synthesis. It binds to penicillin-binding proteins (PBPs), primarily PBP1a, PBP1b, and PBP2, which are essential enzymes involved in the cross-linking of peptidoglycan. This disruption leads to the formation of a defective cell wall and subsequent bacterial lysis [7].
- Spectrum: Imipenem has a wide spectrum of activity against many Gram-positive and Gram-negative bacteria, including many anaerobes. However, it is susceptible to degradation by certain beta-lactamase enzymes.
- Relebactam: A novel beta-lactamase inhibitor.
- Mechanism: Relebactam is a diazabicyclooctane (DBO) derivative. It inhibits a broad range of class A, C, and some class D beta-lactamases, including KPC (Klebsiella pneumoniae carbapenemase) and some OXA carbapenemases, which are responsible for conferring resistance to carbapenems and other beta-lactam antibiotics [8]. Relebactam itself has minimal antibacterial activity but protects imipenem from hydrolysis by these enzymes.
- Synergy: By inhibiting these resistance mechanisms, relebactam restores or enhances the antibacterial activity of imipenem against bacteria that would otherwise be resistant.
- Cilastatin Sodium: A dehydropeptidase-I inhibitor.
- Mechanism: Cilastatin is administered with imipenem to prevent its metabolism by renal dehydropeptidase-I (DHP-I). DHP-I, found in the renal tubules, can rapidly degrade imipenem, reducing its systemic concentration and urinary excretion. Cilastatin inhibits DHP-I, thereby increasing the urinary concentration of active imipenem and preventing nephrotoxic metabolites [9]. This co-administration is crucial for maintaining adequate systemic and urinary levels of active imipenem.
- Combined Action: The combination of imipenem and relebactam provides a potent antimicrobial agent effective against many challenging Gram-negative pathogens, including those producing carbapenemases. Cilastatin ensures the stability and efficacy of imipenem in vivo.
- Pharmacokinetics:
- Administration: Intravenous infusion.
- Distribution: Distributes to various tissues and body fluids.
- Metabolism: Imipenem is metabolized by DHP-I, which is inhibited by cilastatin. Relebactam is minimally metabolized.
- Excretion: Primarily excreted unchanged in the urine by glomerular filtration and tubular secretion. The half-life of imipenem and relebactam is approximately 1 hour.
What are the Key Safety and Efficacy Considerations?
The safety and efficacy profile of imipenem/relebactam with cilastatin sodium (Recarbrio) has been established through clinical trials.
Efficacy:
- cUTI: Demonstrated non-inferiority to meropenem/cilastatin in clinical cure rates, including in patients with pyelonephritis. Effective against pathogens like Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
- HABP/VABP: Demonstrated non-inferiority to piperacillin/tazobactam/cilastatin in all-cause mortality at Day 28. Showed favorable clinical response and microbiological eradication rates, particularly against key pathogens like Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter baumannii (though A. baumannii susceptibility can be variable).
Safety Profile:
- Common Adverse Reactions:
- Diarrhea
- Nausea
- Vomiting
- Infusion-related reactions (e.g., phlebitis)
- Elevated liver enzymes (AST, ALT)
- Serious Adverse Events (SAEs):
- Hypersensitivity reactions (including anaphylaxis).
- Clostridioides difficile-associated diarrhea (CDAD).
- Seizure activity (a known risk with carbapenems, though potentially lower with imipenem compared to some others).
- Hepatotoxicity.
- Renal impairment.
- Contraindications: Hypersensitivity to imipenem, cilastatin, relebactam, or other beta-lactams.
- Precautions: Use with caution in patients with renal impairment, history of seizures, or gastrointestinal disease.
Comparison to Other Agents:
- vs. Meropenem/Vaborbactam: Similar indications for cUTI. Recarbrio has a broader spectrum against Gram-negative bacteria, particularly including Pseudomonas aeruginosa, which is a key target for HABP/VABP. Vaborbactam is more specific for KPC.
- vs. Ceftazidime/Avibactam: Both target resistant Gram-negative pathogens. Ceftazidime/avibactam has a broader spectrum covering Enterobacterales and Pseudomonas aeruginosa, and some activity against Acinetobacter baumannii. Recarbrio's carbapenem backbone offers a different therapeutic option and may be preferred in certain resistance patterns or clinical scenarios.
What is the Intellectual Property Landscape?
The intellectual property surrounding imipenem, cilastatin, and relebactam is complex, involving patents on the active pharmaceutical ingredients (APIs), formulations, methods of use, and manufacturing processes.
- Imipenem and Cilastatin: These are older drugs with extensive patent history. Original patents have long expired. However, patents related to new formulations, combination products, and specific therapeutic uses can still be in force or have been granted.
- Relebactam: As a novel beta-lactamase inhibitor, relebactam is protected by a robust patent portfolio held by Merck & Co., Inc.
- Composition of Matter Patents: These protect the chemical structure of relebactam and its salts or derivatives.
- Formulation Patents: Patents covering specific compositions of imipenem/relebactam and cilastatin in a stable, deliverable form.
- Method of Use Patents: Patents claiming the use of the combination for treating specific infections (e.g., cUTI, HABP/VABP) or infections caused by specific resistant organisms.
- Manufacturing Process Patents: Patents related to novel or improved methods of synthesizing relebactam or the combination product.
- Patent Expiry Dates: The exclusivity period for relebactam and the imipenem/relebactam/cilastatin combination product is critical.
- Relebactam and its associated combination products are protected by patents that extend into the late 2020s and early 2030s in major markets like the U.S. and Europe [10].
- Specific patent expiry dates vary by country and patent family.
- Generic Competition: For imipenem and cilastatin alone, generic versions are widely available. However, the combination with relebactam is currently under patent protection, preventing generic entry.
- Litigation: As drug patents approach expiry or face challenges, patent litigation becomes common. The patent landscape for relebactam and its combinations is subject to potential challenges from generic manufacturers seeking to launch biosimilar or generic versions.
- Market Exclusivity: Beyond patent protection, regulatory exclusivities (e.g., New Chemical Entity (NCE) exclusivity, Orphan Drug Exclusivity) can provide additional market protection periods, separate from patent life. For Recarbrio, as a novel combination product, it has benefited from these exclusivities.
Key Takeaways
- Imipenem/relebactam with cilastatin sodium (Recarbrio) has demonstrated non-inferiority in Phase 3 trials (RESTORE-IMI 1 and 2) for complicated urinary tract infections (cUTIs) and hospital-acquired bacterial pneumonia (HABP)/ventilator-associated bacterial pneumonia (VABP), leading to its FDA approval in 2020.
- The drug targets challenging Gram-negative infections, including those caused by carbapenemase-producing Enterobacterales (CRE) and Pseudomonas aeruginosa, addressing a significant unmet medical need.
- The market for novel antibiotics targeting resistant Gram-negative pathogens is substantial and projected to grow significantly, driven by the rising incidence of antimicrobial resistance (AMR).
- Recarbrio competes with other novel agents like ceftazidime/avibactam and meropenem/vaborbactam, with its specific utility tied to its spectrum of activity and mechanism against specific resistance mechanisms.
- The intellectual property for relebactam and the combination product provides market exclusivity extending into the late 2020s and early 2030s, currently preventing generic competition.
Frequently Asked Questions
-
What specific beta-lactamases does relebactam inhibit?
Relebactam inhibits a broad range of class A, C, and certain class D beta-lactamases, including KPC, AmpC, and some OXA carbapenemases.
-
Does Recarbrio have a role in treating Acinetobacter baumannii infections?
While Acinetobacter baumannii was included in the RESTORE-IMI 2 trial, susceptibility can be variable. Recarbrio demonstrates activity against some strains, but its efficacy for A. baumannii is generally considered less robust than for other targeted pathogens, and specific susceptibility testing is critical.
-
What is the typical dosing regimen for Recarbrio in cUTI and HABP/VABP?
The approved dosing for adults is 1.25 grams (imipenem 500 mg, relebactam 250 mg, cilastatin 500 mg) administered as an intravenous infusion over 30 minutes every 6 hours. For patients with renal impairment, dose adjustments are necessary.
-
Are there any significant drug-drug interactions with Recarbrio?
Potential drug-drug interactions include valproic acid, with which carbapenems can reduce valproic acid concentrations, increasing the risk of breakthrough seizures. Co-administration of probenecid can increase plasma concentrations of imipenem and cilastatin.
-
What are the primary drivers for the development of new antibiotics like relebactam?
The primary drivers are the increasing prevalence of antimicrobial resistance (AMR), particularly among Gram-negative bacteria, leading to a critical shortage of effective treatment options, and the high mortality and morbidity associated with multidrug-resistant infections.
Citations
[1] Merck & Co., Inc. (2019). Merck Announces Positive Top-Line Results from RESTORE-IMI 1, a Phase 3 Study of the Investigational Combination of Imipenem/Cilastatin and Relebactam for Complicated Urinary Tract Infections. [Press Release].
[2] Merck & Co., Inc. (2018). Merck Announces Positive Top-Line Results from RESTORE-IMI 2, a Phase 3 Study of the Investigational Combination of Imipenem/Cilastatin and Relebactam for Hospital-Acquired Bacterial Pneumonia. [Press Release].
[3] U.S. Food and Drug Administration. (2020, April 16). FDA Approves Recarbrio (imipenem, cilastatin and relebactam) for Certain Hospital-Acquired and Ventilator-Associated Bacterial Pneumonias and Complicated Urinary Tract Infections. [Press Release].
[4] World Health Organization. (2017). Global priority list of antimicrobial-resistant bacteria to guide research and development of new antibiotics. Geneva: WHO.
[5] Grand View Research. (2023). Antibiotic Resistance Market Size, Share & Trends Analysis Report.
[6] Fortune Business Insights. (2023). Antibiotics Market Size, Share & COVID-19 Impact Analysis.
[7] Livermore, D. M. (2008). Carbapenemases: ready or not?. Clinical Infectious Diseases, 47(S2), S71-S73.
[8] Rojas, J., et al. (2017). Relebactam, a novel diazabicyclooctane beta-lactamase inhibitor, restores the activity of imipenem against carbapenem-resistant Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 61(10), e00710-17.
[9] Neu, H. C. (1986). Imipenem/cilastatin—a review of 3 years of clinical experience. Reviews of Infectious Diseases, 8(Suppl 3), S324-S331.
[10] U.S. Food and Drug Administration. (n.d.). Drugs@FDA. Retrieved from [FDA Drugs@FDA database - specific patent information is often found within product labels or related FDA documents]. (Note: Specific patent numbers and expiry dates are often found in proprietary databases or through legal searches; this citation points to the FDA resource for official drug information which may indirectly reference patent status through exclusivity periods).
